Skip to main content
SpringerLink
Log in
Book cover

Management of Castration Resistant Prostate Cancer pp 307–320Cite as

Strategies Addressing Quality of Life: Management of Patient-Reported Outcomes and Symptoms

  • Chapter
  • First Online:

  • 848 Accesses

Part of the book series: Current Clinical Urology ((CCU))

Abstract

Patient-reported outcomes (PROs) are an attempt to capture patient experiences often missed with response rates, toxicity data, and survival figures. In this chapter we show why PROs are important, and how physicians treating castrate-resistant prostate cancer (CRPC) patients incorporate PROs into clinical trials and day-to-day practice. We start with an explanation of PROs, illustrate what is currently known about their use in various facets of treatment, and then make recommendations for future use. Rather than providing an exhaustive review of the literature, we highlight the PROs and patient-reported outcome metrics (PROMs) that clinicians may encounter. The chapter then moves to a discussion of measuring pain, common pain syndromes, and evaluation and treatment strategies for pain in CRPC patients. We close with a discussion of treatment strategies for other PROs commonly seen in CRPC patients, including anxiety, depression, fatigue, urination problems, and weight loss.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Osoba D, Tannock IF, Ernst DS, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol. 1999;17(6):1654–63.

    CAS  PubMed  Google Scholar 

  2. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14(6):1756–64.

    CAS  PubMed  Google Scholar 

  3. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.

    Article  CAS  PubMed  Google Scholar 

  4. Bloomfield DJ, Krahn MD, Neogi T, Panzarella T, Smith TJ, Warde P, et al. Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points. J Clin Oncol. 1998;16(6):2272–9.

    CAS  PubMed  Google Scholar 

  5. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999;17(8):2506–13.

    CAS  PubMed  Google Scholar 

  6. Petrylak DP. Chemotherapy for advanced hormone refractory prostate cancer. Urology. 1999;54(6A Suppl):30–5.

    Article  CAS  PubMed  Google Scholar 

  7. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.

    Article  CAS  PubMed  Google Scholar 

  8. Dagher R, Li N, Abraham S, Rahman A, Sridhara R, Pazdur R. Approval summary: docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. Clin Cancer Res. 2004;10(24):8147–51.

    Article  CAS  PubMed  Google Scholar 

  9. Efficace F, Bottomley A, Osoba D, Gotay C, Flechtner H, D'Haese S, et al. Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials-does HRQOL evaluation in prostate cancer research inform clinical decision making? J Clin Oncol. 2003;21(18):3502–11.

    Article  PubMed  Google Scholar 

  10. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0, Published: May 28, 2009 2010. Version 4.03 June 14, 2010. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.

  11. Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol. 2006;7(11):903–9.

    Article  PubMed  Google Scholar 

  12. Chemotherapy-Induced Peripheral Neuropathy: EORTC QLQ-CIPN20. Available from: http://groups.eortc.be/qol/chemotherapy-induced-peripheral-neuropathy-eortc-qlq-cipn20. Cited 29 Sept 2013.

  13. EORTC QLQ-C30. Available from: http://groups.eortc.be/qol/eortc-qlq-c30. Cited 29 Sept 2013.

  14. Basch EM, Reeve BB, Mitchell SA, Clauser SB, Minasian L, Sit L, et al. Electronic toxicity monitoring and patient-reported outcomes. Cancer J. 2011;17(4):231–4.

    Article  PubMed  Google Scholar 

  15. Badalucco S, Reed KK. Supporting quality and patient safety in cancer clinical trials. Clin J Oncol Nurs. 2011;15(3):263–5.

    Article  PubMed  Google Scholar 

  16. Seow H, Sussman J, Martelli-Reid L, Pond G, Bainbridge D. Do high symptom scores trigger clinical actions? An audit after implementing electronic symptom screening. J Oncol Pract. 2012;8(6):e142–8.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Garcia SF, Cella D, Clauser SB, Flynn KE, Lad T, Lai JS, et al. Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. J Clin Oncol. 2007;25(32):5106–12.

    Article  PubMed  Google Scholar 

  18. Bjorner JB, Rose M, Gandek B, Stone AA, Junghaenel DU, Ware Jr JE. Difference in method of administration did not significantly impact item response: an IRT-based analysis from the Patient-Reported Outcomes Measurement Information System (PROMIS) initiative. Quality of Life Res. 2014;23:217–27.

    Article  Google Scholar 

  19. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.

    Article  PubMed  Google Scholar 

  20. Kemmler G, Holzner B, Kopp M, Dunser M, Margreiter R, Greil R, et al. Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. J Clin Oncol. 1999;17(9):2932–40.

    CAS  PubMed  Google Scholar 

  21. Basch E. Patient-Reported Outcomes version of the CTCAE (PRO-CTCAE). Available from: https://wiki.nci.nih.gov/pages/viewpage.action?pageId=10857328. Cited 2 Oct 2013.

  22. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337–43.

    Article  CAS  PubMed  Google Scholar 

  23. Eton DT, Fairclough DL, Cella D, Yount SE, Bonomi P, Johnson DH, et al. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol. 2003;21(8):1536–43.

    Article  PubMed  Google Scholar 

  24. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570–9.

    CAS  PubMed  Google Scholar 

  25. Rothrock NE, Hays RD, Spritzer K, Yount SE, Riley W, Cella D. Relative to the general US population, chronic diseases are associated with poorer health-related quality of life as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS). J Clin Epidemiol. 2010;63(11):1195–204.

    Article  PubMed Central  PubMed  Google Scholar 

  26. Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008. J Clin Epidemiol. 2010;63(11):1179–94.

    Article  PubMed Central  PubMed  Google Scholar 

  27. Hearn J, Higginson IJ. Development and validation of a core outcome measure for palliative care: the palliative care outcome scale. Palliative care core audit project advisory group. Qual Health Care. 1999;8(4):219–27.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Fitzsimmons D, Johnson CD, George S, Payne S, Sandberg AA, Bassi C, et al. Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC study group on quality of life. Eur J Cancer. 1999;35(6):939–41.

    Article  CAS  PubMed  Google Scholar 

  29. Basch E, Autio K, Ryan CJ, Mulders P, Shore N, Kheoh T, et al. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol. 2013;14:1193–9.

    Article  CAS  PubMed  Google Scholar 

  30. Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology. 1997;50(6):920–8.

    Article  CAS  PubMed  Google Scholar 

  31. Belani CP, Brodowicz T, Ciuleanu TE, Krzakowski M, Yang SH, Franke F, et al. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study. Lancet Oncol. 2012;13(3):292–9.

    Article  CAS  PubMed  Google Scholar 

  32. Iyer S, Roughley A, Rider A, Taylor-Stokes G. The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional study. Support Care Cancer. 2014;22:181–7.

    Article  PubMed  Google Scholar 

  33. Hollen PJ, Gralla RJ, Kris MG, Potanovich LM. Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS). Eur J Cancer. 1993;29A Suppl 1:S51–8.

    Article  PubMed  Google Scholar 

  34. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56(6):899–905.

    Article  CAS  PubMed  Google Scholar 

  35. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR, Clinical Significance Consensus Meeting G. Methods to explain the clinical significance of health status measures. Mayo Clin Proc. 2002;77(4):371–83.

    Article  PubMed  Google Scholar 

  36. Quinten C, Maringwa J, Gotay CC, Martinelli F, Coens C, Reeve BB, et al. Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. J Natl Cancer Inst. 2011;103(24):1851–8.

    Article  PubMed Central  PubMed  Google Scholar 

  37. Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009;101(23):1624–32.

    Article  PubMed Central  PubMed  Google Scholar 

  38. Senderowicz AM, Johnson JR, Sridhara R, Zimmerman P, Justice R, Pazdur R. Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas. Oncology. 2007;21(14):1696–706. discussion 706–9, 712, 715.

    PubMed  Google Scholar 

  39. Seal BS, Asche CV, Puto K, Allen PD. Efficacy, Patient-Reported Outcomes (PROs), and tolerability of the changing therapeutic landscape in patients with Metastatic Prostate Cancer (MPC): a systematic literature review. Value Health. 2013;16(5):872–90.

    Article  PubMed  Google Scholar 

  40. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115(16):3670–9.

    Article  CAS  PubMed  Google Scholar 

  41. Beer TM, Schellhammer PF, Corman JM, Glode LM, Hall SJ, Whitmore JB, et al. Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer. Urology. 2013;82(2):410–5.

    Article  PubMed  Google Scholar 

  42. Tannock IF. Personal Communication on September 29. 2013.

    Google Scholar 

  43. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–54.

    Article  PubMed  Google Scholar 

  44. Wu AW, Kharrazi H, Boulware LE, Snyder CF. Measure once, cut twice-adding patient-reported outcome measures to the electronic health record for comparative effectiveness research. J Clin Epidemiol. 2013;66(8 Suppl):S12–20.

    Article  PubMed Central  PubMed  Google Scholar 

  45. Halabi S, Vogelzang NJ, Kornblith AB, Ou SS, Kantoff PW, Dawson NA, et al. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol. 2008;26(15):2544–9.

    Article  PubMed  Google Scholar 

  46. Berthold DR, Pond GR, Roessner M, de Wit R, Eisenberger M, Tannock AI, et al. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res. 2008;14(9):2763–7.

    Article  CAS  PubMed  Google Scholar 

  47. FDA Guidance for Industry. Patient-reported outcome measures use in medical product development to support labeling claims. U.S. Department of Health and Human Services; Silver Spring, MD, 2009.

    Google Scholar 

  48. Basch E, Trentacosti AM, Burke L, Kane R, Atkinson T, Rappaport B, et al. Measurement of pain in metastatic prostate cancer: FDA perspective. In: 2010 genitourinary cancers symposium (ASCO, ASTRO, SUO); March 5–7; San Francisco, 2010.

    Google Scholar 

  49. Docetaxel Prescribing Information (drug label). Available from: http://products.sanofi-aventis.us/Taxotere/taxotere.html. Cited 1 Oct 2013.

  50. Basch E. Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer. Available from: http://clinicaltrials.gov/show/NCT01617174. Cited Oct 3 2013.

  51. Scher HI, Morris MJ, Basch E, Heller G. End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol. 2011;29(27):3695–704.

    Article  PubMed Central  PubMed  Google Scholar 

  52. Eton DT, Shevrin DH, Beaumont J, Victorson D, Cella D. Constructing a conceptual framework of patient-reported outcomes for metastatic hormone-refractory prostate cancer. Value Health. 2010;13(5):613–23.

    Article  PubMed  Google Scholar 

  53. Yount S, Cella D, Banik D, Ashraf T, Shevrin D. Brief assessment of priority symptoms in hormone refractory prostate cancer: the FACT Advanced Prostate Symptom Index (FAPSI). Health Qual Life Outcomes. 2003;1:69.

    Article  PubMed Central  PubMed  Google Scholar 

  54. Carlin BI, Andriole GL. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer. 2000;88(12 Suppl):2989–94.

    Article  CAS  PubMed  Google Scholar 

  55. Scher HI, Chung LW. Bone metastases: improving the therapeutic index. Semin Oncol. 1994;21(5):630–56.

    CAS  PubMed  Google Scholar 

  56. Antonarakis E, Carducci M, Eisenberger M. Treatment of castration-resistant prostate cancer. In: Partin A, editor. Campbell-Walsh urology 10th edition review. Philadelphia: Elsevier Saunders; 2012.

    Google Scholar 

  57. Grossman SA, Lossignol D. Diagnosis and treatment of epidural metastases. Oncology. 1990;4(4):47–54. discussion 5, 8.

    CAS  PubMed  Google Scholar 

  58. Gabriel K, Schiff D. Metastatic spinal cord compression by solid tumors. Semin Neurol. 2004;24(4):375–83.

    Article  PubMed  Google Scholar 

  59. Spinazze S, Caraceni A, Schrijvers D. Epidural spinal cord compression. Crit Rev Oncol Hematol. 2005;56(3):397–406.

    Article  PubMed  Google Scholar 

  60. Rock JP, Ryu S, Yin FF, Schreiber F, Abdulhak M. The evolving role of stereotactic radiosurgery and stereotactic radiation therapy for patients with spine tumors. J Neurooncol. 2004;69(1–3):319–34.

    Article  PubMed  Google Scholar 

  61. Klimo Jr P, Kestle JR, Schmidt MH. Treatment of metastatic spinal epidural disease: a review of the literature. Neurosurg Focus. 2003;15(5):E1.

    Article  PubMed  Google Scholar 

  62. Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol. 2012;13(12):1210–7.

    Article  CAS  PubMed  Google Scholar 

  63. Fizazi K, Scher H, Saad F, Sternberg CN, Miller K, Mulders P, et al. Impact of enzalutamide, an androgen receptor signaling inhibitor, on time to first skeletal related event (SRE) and pain in the phase 3 AFFIRM study. In: 37th European society for medical oncology congress, Vienna; 2012.

    Google Scholar 

  64. Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20.

    Article  CAS  PubMed  Google Scholar 

  65. Lewington VJ, McEwan AJ, Ackery DM, Bayly RJ, Keeling DH, Macleod PM, et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer. 1991;27(8):954–8.

    Article  CAS  PubMed  Google Scholar 

  66. Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol. 2005;6(6):392–400.

    Article  CAS  PubMed  Google Scholar 

  67. Parker, C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, et al., Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med, 2013. 369(3): p. 213–223.

    Google Scholar 

  68. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458–68.

    Article  CAS  PubMed  Google Scholar 

  69. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012;379(9810):39–46.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  70. Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013;31(4):412–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  71. Adamsen L, Quist M, Andersen C, Moller T, Herrstedt J, Kronborg D, et al. Effect of a multimodal high intensity exercise intervention in cancer patients undergoing chemotherapy: randomised controlled trial. BMJ. 2009;339:b3410.

    Article  PubMed Central  PubMed  Google Scholar 

  72. Bruera E, Valero V, Driver L, Shen L, Willey J, Zhang T, et al. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol. 2006;24(13):2073–8.

    Article  CAS  PubMed  Google Scholar 

  73. Lower EE, Fleishman S, Cooper A, Zeldis J, Faleck H, Yu Z, et al. Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manage. 2009;38(5):650–62.

    Article  CAS  PubMed  Google Scholar 

  74. Barton DL, Liu H, Dakhil SR, Linquist B, Sloan JA, Nichols CR, et al. Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst. 2013;105(16):1230–8.

    Article  PubMed  Google Scholar 

  75. Bruera E, Roca E, Cedaro L, Carraro S, Chacon R. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep. 1985;69(7–8):751–4.

    CAS  PubMed  Google Scholar 

  76. Yennurajalingam S, Frisbee-Hume S, Palmer JL, Delgado-Guay MO, Bull J, Phan AT, et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol. 2013;31(25):3076–82.

    Article  CAS  PubMed  Google Scholar 

  77. Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol. 2002;20(2):567–73.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Johns Hopkins Hospital, Baltimore, MD, 21231, USA

    Channing J. Paller MD

  2. Palliative Medicine, Johns Hopkins Medical Institutions, Baltimore, MD, USA

    Thomas J. Smith MD, FACP, FASCO, FAAHPM

  3. Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA

    Thomas J. Smith MD, FACP, FASCO, FAAHPM

  4. Palliative Medicine, Baltimore, MD, USA

    Thomas J. Smith MD, FACP, FASCO, FAAHPM

Authors
  1. Channing J. Paller MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas J. Smith MD, FACP, FASCO, FAAHPM
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Channing J. Paller MD .

Editor information

Editors and Affiliations

  1. Department of Surgery, University of Montreal Hospital Center, Montreal, Québec, Canada

    Fred Saad

  2. Department of Oncology, The Johns Hopkins University, Baltimore, Maryland, USA

    Mario A. Eisenberger

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Paller, C.J., Smith, T.J. (2014). Strategies Addressing Quality of Life: Management of Patient-Reported Outcomes and Symptoms. In: Saad, F., Eisenberger, M. (eds) Management of Castration Resistant Prostate Cancer. Current Clinical Urology. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-1176-9_22

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1176-9_22

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-1175-2

  • Online ISBN: 978-1-4939-1176-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation